[go: up one dir, main page]

MX2022008479A - Combinaciones de brimonidina de dosis baja y usos de las mismas. - Google Patents

Combinaciones de brimonidina de dosis baja y usos de las mismas.

Info

Publication number
MX2022008479A
MX2022008479A MX2022008479A MX2022008479A MX2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A
Authority
MX
Mexico
Prior art keywords
combinations
low
present
brimonidine
dose
Prior art date
Application number
MX2022008479A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Eye Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Therapies Llc filed Critical Eye Therapies Llc
Publication of MX2022008479A publication Critical patent/MX2022008479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones que contienen brimonidina de dosis baja y ya sea un segundo fármaco para glaucoma, una anti-histamina o un fármaco anti-inflamatorio no esteroideo; la presente invención se dirige además, a métodos para tratar glaucoma o alergias o reducir la inflamación administrando composiciones de la presente invención.
MX2022008479A 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas. MX2022008479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516931P 2017-06-08 2017-06-08
US201862621082P 2018-01-24 2018-01-24

Publications (1)

Publication Number Publication Date
MX2022008479A true MX2022008479A (es) 2022-08-02

Family

ID=64562826

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019014748A MX2019014748A (es) 2017-06-08 2018-06-07 Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022008478A MX2022008478A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022008479A MX2022008479A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019014748A MX2019014748A (es) 2017-06-08 2018-06-07 Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022008478A MX2022008478A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Country Status (13)

Country Link
US (2) US20180353504A1 (es)
EP (1) EP3634415A4 (es)
JP (3) JP2020523312A (es)
KR (2) KR20200018580A (es)
CN (2) CN110996954A (es)
AU (2) AU2018279074B2 (es)
BR (1) BR112019025987A2 (es)
CA (1) CA3066398A1 (es)
CL (3) CL2019003572A1 (es)
MX (3) MX2019014748A (es)
MY (1) MY205909A (es)
SG (1) SG11201911750RA (es)
WO (2) WO2018226942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3818010A4 (en) 2018-07-03 2022-08-17 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
MX2022014959A (es) 2020-05-27 2023-01-11 Lupin Ltd Composiciones de nanoemulsiónes oftálmicas.
JP2022075651A (ja) * 2020-11-06 2022-05-18 千寿製薬株式会社 眼科用液体製剤
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物
ITMI20070890A1 (it) * 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
AU2008344909B2 (en) * 2007-10-16 2013-06-06 Sun Pharma Advanced Research Company Limited Ophthalmic composition comprising a prostaglandin
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) * 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
PT3943069T (pt) * 2009-03-17 2025-02-21 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
EP2408302A4 (en) * 2009-03-17 2012-08-15 Aciex Therapeutics Inc OPHTALMIC FORMULATIONS OF KTOTICENE AND METHODS OF USE
US20100311688A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US8445526B2 (en) * 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
US20130203813A1 (en) * 2011-05-04 2013-08-08 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
WO2013013143A1 (en) * 2011-07-20 2013-01-24 Allergan, Inc. Fixed dose combination of bimatoprost and brimonidine
US20140194527A1 (en) * 2012-02-29 2014-07-10 Rohto Usa, Inc. Geranylgeranylacetone formulations and retinal delivery thereof
EP2841104A1 (en) * 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US9833441B2 (en) * 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
WO2015138786A1 (en) * 2014-03-12 2015-09-17 The Trustees Of Columbia University In The City Of New York Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents
CA2998134A1 (en) * 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
US20200197398A1 (en) * 2017-06-08 2020-06-25 Eye Therapies, Llc Netarsudil and low-dose brimonidine combination and uses thereof

Also Published As

Publication number Publication date
EP3634415A1 (en) 2020-04-15
AU2023282222B2 (en) 2025-06-26
AU2023282222A1 (en) 2024-01-04
RU2019144001A (ru) 2021-07-09
CN117122600A (zh) 2023-11-28
CL2022002566A1 (es) 2023-05-26
CL2019003572A1 (es) 2020-04-24
JP2020523312A (ja) 2020-08-06
KR20240090655A (ko) 2024-06-21
MX2019014748A (es) 2020-08-03
EP3634415A4 (en) 2021-03-17
WO2019236148A1 (en) 2019-12-12
SG11201911750RA (en) 2020-01-30
AU2018279074B2 (en) 2023-12-14
RU2019144001A3 (es) 2022-03-05
AU2018279074A1 (en) 2020-01-16
US20180353504A1 (en) 2018-12-13
US20220233524A1 (en) 2022-07-28
CN110996954A (zh) 2020-04-10
CL2022002564A1 (es) 2023-05-26
CA3066398A1 (en) 2018-12-13
JP2024164101A (ja) 2024-11-26
KR20200018580A (ko) 2020-02-19
WO2018226942A1 (en) 2018-12-13
BR112019025987A2 (pt) 2020-06-30
JP2023055823A (ja) 2023-04-18
MX2022008478A (es) 2022-08-02
MY205909A (en) 2024-11-20

Similar Documents

Publication Publication Date Title
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
JOP20220008A1 (ar) مثبطات parp1
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016500024A1 (en) Bromodomain inhibitor
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
PH12016502352A1 (en) Pharmaceutical composition
MX390051B (es) Antagonistas de ep4.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
TW201613578A (en) Pharmaceutical combinations
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
EP4420726A3 (en) Fixed dose combination of bromonidine and timolol
EP4356962A3 (en) Selective il-6-trans-signalling inhibitor compositions
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer